The Full Wiki

Opipramol: Wikis


Note: Many of our articles have direct quotes from sources you can cite, within the Wikipedia article! This article doesn't yet, but we're working on it! See more info or our list of citable articles.


From Wikipedia, the free encyclopedia

Systematic (IUPAC) name
CAS number 315-72-0
ATC code N06AA05
PubChem 9417
Chemical data
Formula C 23H29N3O 
Mol. mass 363.496
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Pregnancy cat.  ?
Legal status
Routes  ?

Opipramol (Insidon, Pramolan, Ensidon, Oprimol) is an antidepressant and anxiolytic used in Germany and other European countries.[1][2] Although it is a member of the tricyclic antidepressants, opipramol's primary mechanism of action is much different in comparison.[2] Most TCAs act as reuptake inhibitors, but opipramol does not, and instead acts as a sigma receptor agonist, among other properties.[2]



Opipramol is typically used in the treatment of generalized anxiety disorder (GAD).[1] Its anxiolysis becomes prominent after only 1-2 weeks of chronic administration. Upon first commencing treatment, opipramol is rather sedating in nature due to its antihistamine properties, but this effect becomes less prominent with time.


Opipramol acts as a high affinity sigma receptor agonist primarily at the σ1 subtype, but also at the σ2 subtype with somewhat lower affinity.[1] It is this property which is responsible for its therapeutic benefits against anxiety and depression.[2] Opipramol also acts as a low to moderate affinity antagonist for the D2, 5-HT2, H1, H2, and muscarinic acetylcholine receptors. H1 and H2 receptor antagonism account for its antihistamine effects, and muscarinic acetylcholine receptor antagonism is responsible for its anticholinergic properties.[1]


Opipramol should not be taken with alcohol, or in patients with benign prostatic hyperplasia (BPH) or glaucoma.

See also


  1. ^ a b c d Möller HJ, Volz HP, Reimann IW, Stoll KD (February 2001). "Opipramol for the treatment of generalized anxiety disorder: a placebo-controlled trial including an alprazolam-treated group". Journal of Clinical Psychopharmacology 21 (1): 59–65. PMID 11199949.  
  2. ^ a b c d Müller WE, Siebert B, Holoubek G, Gentsch C (November 2004). "Neuropharmacology of the anxiolytic drug opipramol, a sigma site ligand". Pharmacopsychiatry 37 Suppl 3: S189–97. doi:10.1055/s-2004-832677. PMID 15547785.  

Got something to say? Make a comment.
Your name
Your email address